Biocon posts 9% rise in Q3FY26 revenue to Rs 4,173 crore; net profit jumps to Rs 143.8 crore on strong generics and ...

Biocon Ltd.’s December quarter net profit rose 475 percent to Rs.144 crore in Q3FY26 from Rs.25 crore a year earlier, ...

Biocon’s Q3 revenue and EBITDA missed estimates, while profit rose sharply on a low base despite a ₹293 crore exceptional loss. The company also moved to fully integrate Biocon Biologics.

Biocon Limited on Thursday reported a 5.7-fold year-on-year (YoY) increase in consolidated net profit attributable to the shareholders of the company, reaching ₹144 crore for the quarter ended ...

After cutting debt and raising $1 billion, Biocon sharpens its biosimilars and GLP-1 play, betting on scale, regulatory ...

Biocon in Q3 clocks revenue of Rs. 4,290 crore, up 11%, net profit at Rs. 144 crore up 475%: Our Bureau, Bengaluru Friday, February 13, 2026, 12:10 Hrs [IST] Biocon for the fiscal ...

The Bengaluru-based company on 14 January said it raised $460 million via a QIP of shares to buy out Mylan Inc’s (Viatris) stake in its arm Biocon Biologics. Days later, it announced the acquisition ...

Biocon Limited ( (IN:BIOCON)) has issued an update. Biocon Limited has significantly increased its stake in its unlisted material subsidiary, Biocon Biologics Limited (BBL), through a combination of a ...

Fitch Ratings revises Biocon Biologics Limited outlook to Positive, affirms BB- rating, citing Biocon Limited’s improving ...

PITTSBURGH and BENGALURU, India, July 28, 2021 /PRNewswire/ — Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug ...